Loading

Please wait...

Afrezza

Generic Name: insulin (inhalation) (IN soo lin IN ha LAY tion)
Brand Names: Afrezza
Afrezza (insulin human) Inhalation Powder is used to treat diabetes. Includes Afrezza side effects, interactions and indications.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Afrezza Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Afrezza (insulin inhalation) is a rapid-acting form of human insulin that is inhaled through the mouth. Insulin is a hormone that works by lowering levels of Glucose (sugar) in the blood. Afrezza inhalation is a fast-acting insulin that starts to work about 15 minutes after inhalation, peaks in about 1 hour, and keeps working for 2 to 4 hours. Afrezza inhalation is used to improve blood sugar control in adults with diabetes mellitus. If you have type 1 diabetes, you will also need to use a long-acting injectable insulin. Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Afrezza Side Effects

Note: This document contains side effect information about insulin inhalation, rapid acting. Some of the dosage forms listed on this page may not apply to the brand name Afrezza.

For the Consumer

Applies to insulin inhalation, rapid acting: inhalation aerosol powder

Warning

Inhalation route (Aerosol Powder)

Acute bronchospasm has been observed in patients with asthma and COPD using insulin, human inhaled. Insulin, human inhaled, is contraindicated in patients with chronic lung disease such as asthma or COPD. Before initiating insulin, human inhaled, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.

Along with its needed effects, insulin inhalation, rapid acting (the active ingredient contained in Afrezza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin inhalation, rapid acting:

More common

  • Anxiety
  • blurred vision
  • chills
  • cold sweats
  • coma
  • confusion
  • cool, pale skin
  • cough
  • depression
  • dizziness
  • fast heartbeat
  • headache
  • increased hunger
  • nausea
  • nightmares
  • seizures
  • shakiness
  • slurred speech
  • unusual tiredness or weakness

Incidence not known

  • Difficulty breathing
  • difficulty swallowing
  • hives, itching, or skin rash
  • noisy breathing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • tightness in the chest

Some side effects of insulin inhalation, rapid acting may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Diarrhea
  • sore throat

Incidence not known

  • Weight gain

For Healthcare Professionals

Applies to insulin inhalation, rapid acting: inhalation powder

Respiratory

In clinical trials of up to 2 years duration, a 15% or greater reduction in forced expiratory volume (FEV1) occurred in 6% of patients treated with inhaled insulin compared with a 3% decline in patients receiving comparator anti-diabetes treatment. Patients with chronic lung disease were not included in these studies. The FEV1 decline occurred during the first 3 months and persisted; it did not appear to worsen with increased duration of use. The changes in FEV1 were similar in patients with type 1 and type 2 diabetes mellitus.

Very common (10% or more): Cough (25.6% to 29.4%)

Common (1% to 10%): Bronchitis, productive cough, decreased pulmonary function test

Metabolic

Very common (10% or more): Hypoglycemia, non-severe (67%)

Common (1% to 10%): Hypoglycemia, severe

Uncommon (0.1% to 1%): Diabetic ketoacidosis

Frequency not reported: Weight gain

Diabetic ketoacidosis:

In patients with type 1 diabetes, diabetic ketoacidosis occurred in 0.43% (n= 13) of patients who received inhaled insulin compared with 0.14% (n=3) of patients receiving subcutaneous insulin.

Hypoglycemia:

The incidence of non-severe hypoglycemia in patients with type 2 diabetes was 67%. The incidence of severe hypoglycemia was reported at 5.1%. A severe episode was defined as a hypoglycemic event requiring assistance of another person and associated with either a blood glucose value consistent with hypoglycemia or prompt recovery following treatment. A non-severe episode was defined as symptoms of hypoglycemia with or without a low blood glucose value. The incidence of hypoglycemia was not reported for patients with type 1 diabetes.

Weight gain:

In patients with type 2 diabetes mellitus who received inhaled insulin therapy, a mean weight gain of 0.49 kg occurred compared with a mean weight loss of 1.13 kg in placebo-treated patients.

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea

General

The most common adverse reactions reported included hypoglycemia, cough, throat pain or irritation.

The most common reason for drug discontinuation was cough.

Local

Common (1% to 10%): Throat pain or irritation

Genitourinary

Common (1% to 10%): Urinary tract infection

Oncologic

During clinical trials, 2 cases of lung cancer were reported; in both cases, heavy tobacco use was reported. Following completion of clinical trials, 2 cases of squamous cell lung cancer were reported in non-smokers.

Frequency not reported: Lung cancer

Other

Common (1% to 10%): Fatigue

Psychiatric

Common (1% to 10%): Headache

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Afrezza (www.drugs.com/afrezza.html).